Neuphoria Therapeutics Inc.
Neuphoria Therapeutics Inc. (Nasdaq: NEUP) is a clinical-stage biotechnology company whose activities now center on a proposed merger with Scancell Holdings, preserving cash, maintaining corporate obligations, and managing intellectual property and partnered-program interests. Its lead asset, BNC210, is an oral… From the company’s description.
In fiscal 2026, Neuphoria Therapeutics Inc. reported revenue of $1.17M, down 92.5% from fiscal 2025, and a net loss of $13.45M. Operations used $12.35M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure.
What Neuphoria Therapeutics Inc. does
In the company’s own words
Neuphoria Therapeutics Inc. (Nasdaq: NEUP) is a clinical-stage biotechnology company whose activities now center on a proposed merger with Scancell Holdings, preserving cash, maintaining corporate obligations, and managing intellectual property and partnered-program interests. Its lead asset, BNC210, is an oral small-molecule negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor, historically developed for anxiety and stress-related disorders. The company discontinued BNC210 development for social anxiety disorder after its Phase 3 trial failed to meet the primary endpoint; its PTSD program is clinic-ready but has no active trial. Neuphoria has no reportable business segments described in its current portfolio. Partnered programs include Merck’s alpha7 positive allosteric modulators for cognitive disorders, Pfizer’s KAT6 program, and Carina Biotech’s CNA3103 cell therapy candidate; partners control their development. Neuphoria may receive milestones, royalties, distributions, or sublicensing proceeds from these programs. A fiscal 2026 restructuring ended leases, halted or paused most internal research and development, and left the company with one full-time employee. Neuphoria became the successor to Australia-based Bionomics after redomiciling to Delaware in December 2024.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- BURLINGTON, MA
- Fiscal year end
- June
- CIK
- 1191070
- SIC
- 2834
Financial performance, year by year
Fiscal 2024–2026 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Neuphoria Therapeutics Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Neuphoria Therapeutics Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Neuphoria Therapeutics Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Neuphoria Therapeutics Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Neuphoria Therapeutics Inc.'s last four quarterly filings that the numbers alone won't show?”